-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amitriptyline Hydrochloride in Erythromelalgia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amitriptyline Hydrochloride in Erythromelalgia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amitriptyline Hydrochloride in Erythromelalgia Drug Details: Amitriptyline hydrochloride is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Diakine-DK210 (EGFR) in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Diakine-DK210 (EGFR) in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Diakine-DK210 (EGFR) in Solid Tumor Drug Details: Diakine-DK210 (EGFR) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-637 in Transitional Cell Cancer (Urothelial Cell Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-637 in Transitional Cell Cancer (Urothelial Cell Cancer) Drug Details: ABBV-637 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – REGN-5837 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - REGN-5837 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. REGN-5837 in B-Cell Non-Hodgkin Lymphoma Drug Details: REGN-5837 is under development...
-
Product Insights
Epidermolysis Bullosa – Drugs In Development, 2023
Global Markets Direct’s, ‘Epidermolysis Bullosa - Drugs In Development, 2023’, provides an overview of the Epidermolysis Bullosa pipeline landscape. The report provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Gastrointestinal Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastrointestinal Tumor - Drugs In Development, 2023’, provides an overview of the Gastrointestinal Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastrointestinal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NUV-655 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NUV-655 in Non-Small Cell Lung Cancer Drug Details: NUV-655 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inezetamab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inezetamab in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inezetamab in Solid Tumor Drug Details: Inezetamab (AMG-994) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GC-101 in Metastatic Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GC-101 in Metastatic Melanoma Drug Details: GC-101 is under development for the treatment of gastrointestinal...